MedicaidPrior AuthMedium impact
Columvi™ (glofitamab-gxbm) (Revised)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Louisiana Medicaid now requires prior authorization for Columvi (glofitamab-gxbm), a cancer drug for relapsed/refractory large B-cell lymphoma. Coverage requires specific diagnosis criteria, two or more prior systemic therapies, and monotherapy use.
Action Required
By January 1, 2026: Billing team must implement prior authorization requirements for Columvi (glofitamab-gxbm) for Louisiana Medicaid patients. Verify patients meet all criteria: diagnosis of DLBCL or LBCL from follicular lymphoma, two or more prior systemic therapies, and monotherapy use. Visit www.humana.com/PAL for medical coding information. Claims will be denied without proper prior authorization.